We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to continue to investigate ...

Morning Live's Dr Xand van Tulleken discussed common causes of pins and needles and when to worry ...

Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, ...

Dr Xand shared common causes of pins and needles that should be a concern and warrant booking a GP appointment. The list ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.

PHOENIX -- A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial. Patients with ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM ESTCompany ParticipantsKave Niksefat - Senior Vice President of ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...

Dr. Kimberly Patton sits down with Brittany K to discuss 3 possible causes of neuropathy that a lot of people are unaware of. Nerve damage can be caused by post-surgery trauma, ...

One of the great pleasures for me in writing this weekly column is the feedback I receive from you, the readers.

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half ...

While vigilant foot care can lead to a reduction in itching, the most important thing you can do is work on improved blood sugar control.